Page 1 | Search Results | Blood | American Society of Hematology

Skip Nav Destination

1-20 of 21

Sort by

Sort Order Select

Journal Articles

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

Blood (2025) 146 (Supplement 1): 5996.

https://doi.org/10.1182/blood-2025-5996

Published: 2025

Journal Articles

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Blood (2025) 146 (Supplement 1): 5994.

https://doi.org/10.1182/blood-2025-5994

Published: 2025

Journal Articles

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Blood (2025) 146 (Supplement 1): 5951.

https://doi.org/10.1182/blood-2025-5951

Published: 2025

Journal Articles

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Blood (2025) 146 (Supplement 1): 592.

https://doi.org/10.1182/blood-2025-592

Published: 2025

Journal Articles

Optimizing essential, complex hematologic care for patients living with disabilities

Blood (2025) 146 (Supplement 1): 4392.

https://doi.org/10.1182/blood-2025-4392

Published: 2025

Journal Articles

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Blood (2025) 146 (Supplement 1): 378.

https://doi.org/10.1182/blood-2025-378

Published: 2025

Journal Articles

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Blood (2025) 146 (Supplement 1): 1869.

https://doi.org/10.1182/blood-2025-1869

Published: 2025

Journal Articles

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Yosra Aljawai, Denai Milton, Rohtesh Mehta, David Marin, Yago Nieto, George Chen, Betul Oran, Portia Smallbone, Chitra Hosing, Oren Pasvolsky, Amin Alousi, Partow Kebriaei, Uday Popat, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 168.

https://doi.org/10.1182/blood-2025-168

Published: 2025

Journal Articles

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Blood (2025) 146 (Supplement 1): 6058.

https://doi.org/10.1182/blood-2025-6058

Published: 2025

Journal Articles

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Jeremy Ramdial, Portia Smallbone, Roland Bassett, David Marin, Richard Champlin, Elizabeth Shpall, Partow Kebriaei

Blood (2025) 146 (Supplement 1): 2515.

https://doi.org/10.1182/blood-2025-2515

Published: 2025

Journal Articles

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

Betul Oran, Peter Thall, Gheath Alatrash, Jin Im, Jeremy Ramdial, Roland Bassett, Uday Popat, Partow Kebriaei, Portia Smallbone, Jessica Jewell, Richard Champlin, Elizabeth Shpall

Blood (2025) 146 (Supplement 1): 2511.

https://doi.org/10.1182/blood-2025-2511

Published: 2025

Journal Articles

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Blood (2024) 144 (Supplement 1): 3514.

https://doi.org/10.1182/blood-2024-211371

Published: 2024

Journal Articles

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Blood (2024) 144 (Supplement 1): 506.

https://doi.org/10.1182/blood-2024-203338

Published: 2024

Journal Articles

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Yosra M. Aljawai, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Portia Smallbone, Katayoun Rezvani, Richard E. Champlin, Elizabeth J. Shpall, Rohtesh S. Mehta

Blood (2024) 144 (Supplement 1): 7441.

https://doi.org/10.1182/blood-2024-210279

Published: 2024

Journal Articles

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Yosra M. Aljawai, Rima M. Saliba, George Chen, Betul Oran, Warren B. Fingrut, Amin M. Alousi, Qaiser Bashir, Chitra Hosing, Partow Kebriaei, David Marin, Amanda L. Olson, Uday Popat, Muzaffar H. Qazilbash, Jeremy Ramdial, Gabriela Rondon, Portia Smallbone, Samer A. Srour, Richard E. Champlin, Elizabeth J. Shpall

Blood (2024) 144 (Supplement 1): 7442.

https://doi.org/10.1182/blood-2024-210407

Published: 2024

Journal Articles

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

Blood (2024) 144 (Supplement 1): 5154.

https://doi.org/10.1182/blood-2024-203824

Published: 2024

Journal Articles

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Portia Smallbone, Kai Cao, Rima M. Saliba, Michele Alvarez, Warren B Fingrut, Yosra Aljawai, Amanda L. Olson, Amin M. Alousi, George Chen, Jeremy Ramdial, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 4937.

https://doi.org/10.1182/blood-2024-200238

Published: 2024

Journal Articles

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Natalie Rafaeli, Rima M. Saliba, Jayastu Senapati, Naval Daver, Portia Smallbone, Partow Kebriaei, David Marin, Uday Popat, Tapan M. Kadia, Farhad Ravandi, George Chen, Richard E. Champlin, Elizabeth J. Shpall, Betul Oran

Blood (2024) 144 (Supplement 1): 2191.

https://doi.org/10.1182/blood-2024-201718

Published: 2024

Journal Articles

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Pietro R Di Ciaccio, Belinda Campbell, Kylie D Mason, Mohamed Shanavas, Matthew Greenwood, Gareth P Gregory, Renee Eslick, Giselle Kidson-Gerber, Catherine Tang, Kirk L Morris, Portia Smallbone, Xavier Badoux, Michael J Shipton, Sean J McKeague, Jenna Langfield, Kathryn Goss, Nada Hamad

Blood (2021) 138 (Supplement 1): 882.

https://doi.org/10.1182/blood-2021-150538

Published: 2021

Journal Articles

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Portia Smallbone, MBBS, Stephanie Clugston, MBBS (Hons), Rebecca De Kraa, BSc, Duncan Purtill, MBBS,FRCPA,FRACP, Matthew Wright, MBBS, FRCPA, FRACP, Michael F. Leahy, FRACP,FRCPath,FRCP, M Hasib Sidiqi, MBBS

Blood (2020) 136 (Supplement 1): 23.

https://doi.org/10.1182/blood-2020-141783

Published: 2020

Update search

NARROW

Publications

Format

Article Type

Date

Availability

MMF is associated with higher non-relapse mortality and inferior survival in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide based gvhd prophylaxis

CD34+/TNC ratio predicts relapse in AML/MDS patients receiving peripheral blood matched allogeneic stem cell transplantation with post-transplant cyclophosphamide

Administration of off-the-shelf, expanded, most closely HLA matched, third party viral specific T cells for the therapy of adenovirus related disease in adult immunocompromised patients.

Clonal dynamics of FLT3-ITD positive acute myeloid leukemia following relapse after allogeneic stem cell transplantation

Optimizing essential, complex hematologic care for patients living with disabilities

Myeloablative fractionated busulfan, fludarabine, cladribine, thiotepa, and venetoclax (Cladillac) conditioning for high-risk AML: A phase 2 trial

Allogeneic stem cell transplant for T-prolymphocytic leukemia: A single center analysis

Older donor age is not associated with inferior survival in contemporary haploidentical transplantation

Persistent symptom burden and unmet needs in long-term survivors of allogeneic hematopoietic cell transplantation: An analysis using the MD anderson symptom inventory (MDASI-BMT)

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for acute lymphoblastic leukemia following allogeneic stem cell transplantation

Phase II trial of venetoclax in combination with azacitidine as maintenance therapy for high-risk acute leukemia following allogeneic stem cell transplantation

Fractionated Busulfan, Fludarabine and Thiotepa Myeloablative Conditioning to Improve Transplant Outcomes for Myelofibrosis

Myeloablative Fractionated Busulfan, Fludarabine, Cladribine, Thiotepa and Venetoclax (Cladillac) Conditioning Regimen for Very High-Risk AML/MDS: A Phase 2 Trial

Impact of Donor Age and Donor-Recipient Sex Mismatch on HLA-Matched Related and Unrelated Donor Hematopoietic Cell Transplantation Outcomes

Improved Outcomes of Haploidentical Hematopoietic Stem Cell Transplantation with Younger Donors

Impact of Ethnicity on Long Term Outcomes of High-Dose Chemotherapy and Upfront Autologous Hematopoietic Stem Cell Transplantation in Patients with Multiple Myeloma

HLA-DPB1 Mismatches and the Impact on Unrelated Donor Transplant Outcomes with the Use of Post-Transplant Cyclophosphamide

Primary Induction Failure Acute Myeloid Leukemia: Immediate Use of Allogeneic Stem Cell Transplantation Vs. Further Induction Chemotherapy

Lymphoma during Pregnancy: A Multicentre Study By the Australasian Lymphoma Alliance

Presence of Multiple High Risk Cytogenetic Abnormalities Is Associated with Rapid Progression and Shorter Survival in Newly Diagnosed Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only